Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence
Open Access
- 16 December 2020
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (5) , 1496-1519
Abstract
Hepatitis A virus (HAV) infections continue to represent a significant disease burden causing approximately 200 million infections, 30 million symptomatic illnesses and 30,000 deaths each year. Effective and safe hepatitis A vaccines have been available since the early 1990s. Initially developed for individual prophylaxis, HAV vaccines are now increasingly used to control hepatitis A in endemic areas. The human enteral HAV is eradicable in principle, however, HAV eradication is currently not being pursued. Inactivated HAV vaccines are safe and, after two doses, elicit seroprotection in healthy children, adolescents, and young adults for an estimated 30–40 years, if not lifelong, with no need for a later second booster. The long-term effects of the single-dose live-attenuated HAV vaccines are less well documented but available data suggest they are safe and provide long-lasting immunity and protection. A universal mass vaccination strategy (UMV) based on two doses of inactivated vaccine is commonly implemented in endemic countries and eliminates clinical hepatitis A disease in toddlers within a few years. Consequently, older age groups also benefit due to the herd protection effects. Single-dose UMV programs have shown promising outcomes but need to be monitored for many more years in order to document an effective immune memory persistence. In non-endemic countries, prevention efforts need to focus on ‘new’ risk groups, such as men having sex with men, prisoners, the homeless, and families visiting friends and relatives in endemic countries. This narrative review presents the current evidence regarding the immunological and epidemiological long-term effects of the hepatitis A vaccination and finally discusses emerging issues and areas for research.Keywords
This publication has 210 references indexed in Scilit:
- Hepatitis A in Puglia (South Italy) after 10 years of universal vaccination: need for strict monitoring and catch-up vaccinationBMC Infectious Diseases, 2012
- Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in ArgentinaHepatic Medicine: Evidence and Research, 2012
- Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A VirusPLOS Computational Biology, 2012
- Hepatitis A: Epidemiology and prevention in developing countriesWorld Journal of Hepatology, 2012
- Challenges to mapping the health risk of hepatitis A virus infectionInternational Journal of Health Geographics, 2011
- Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination programHepatic Medicine: Evidence and Research, 2011
- Long-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected AdultsThe Journal of Infectious Diseases, 2011
- Hepatitis A Virus Vaccine Escape Variants and Potential New Serotype EmergenceEmerging Infectious Diseases, 2011
- Successful Memory Response following a Booster Dose with a Virosome-Formulated Hepatitis A Vaccine Delayed Up to 11 YearsClinical and Vaccine Immunology, 2011
- Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal®) in the ElderlyJournal of Travel Medicine, 2006